Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Isotope & Radiation Corp. ( (HK:1763) ) has issued an update.
China Isotope & Radiation Corporation has warned investors that its 2025 revenue is expected to fall to about RMB6.98 billion–RMB7.21 billion, a year-on-year decline of roughly 5%–8%. Net profit is projected at RMB611 million–RMB655 million, down about 25%–30%, with profit attributable to equity shareholders seen dropping around 20%–25% versus 2024.
The company said operations remain normal, attributing the revenue decline mainly to weaker performance in its nuclear medical equipment segment and the sharper profit drop to supplementary tax payments and late fees at subsidiary Shenzhen Zhonghe Headway Bio-Sci & Tech. Management stressed that the figures are based on unaudited management accounts and may change when full-year 2025 results are released by the end of March 2026, and it urged shareholders and potential investors to exercise caution when trading the stock.
The most recent analyst rating on (HK:1763) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.
More about China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is a Hong Kong–listed joint stock company based in the PRC that operates in the nuclear medicine and radiation sector. The group’s businesses include nuclear medical equipment and related isotope and radiation technologies, serving healthcare and industrial customers in China and potentially broader regional markets.
Average Trading Volume: 253,385
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.86B
See more insights into 1763 stock on TipRanks’ Stock Analysis page.